DUBLIN--(BUSINESS WIRE)--The "Global Insomnia Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.
The global insomnia treatment drugs market was valued at US$ 2,689.6 million in 2017, and is expected to reach US$ 4,332.4 million by 2026, expanding at a CAGR of 5.5% from 2018 to 2026.
Pharmaceutical companies are relentlessly working to provide effective medication with least side effects. Orexin antagonist (Belsomra) are being prescribed by physicians throughout the globe owing to its ability to improve sleep with high degree of tolerability and limited adverse effects profile. The insomnia treatment drugs market pose severe threat from alternative treatment such as cognitive behavioral therapy for insomnia (CBTI) and recent FDA approval of devices such as Fisher Wallace Stimulator and EBB Insomnia Therapy.
Prescription sleep aids dominate the treatment type segment on account of key factors such as rising prevalence of insomnia, increasing stress, addiction, etc., which if untreated will eventually result in chronic illness. Demanding lifestyle and poor sleeping habits result in secondary insomnia which requires benzodiazepines in combination with zolpidem for its treatment.
Key Market Movements
- Increasing number of geriatric population suffering with sleep disorders in the developed nations
- Affordable reimbursement scenario for drugs prescribed in insomnia treatment
- Growing health awareness leading to effective insomnia treatment, and developing healthcare infrastructure drive the market growth in developing nations
Key Topics Covered
Chapter 1. Preface
Chapter 2. Executive Summary
Chapter 3. Insomnia Treatment Drugs Market: Dynamics and Future Outlook
Chapter 4. Global Insomnia Treatment Drugs Market, by Treatment Type
Chapter 5. Global Insomnia Treatment Drugs Market, by Geography
Chapter 6. Company Profiles
- F.Hoffman La-Roche AG
- Merck & Co. Inc.
- Mylan N.V.
- Pernix Therapeutics
- Pfizer Inc.
- Sanofi S.A.
- Sumitomo Dainippon Pharma Co. Ltd.
- Takeda Pharmaceutical Company Ltd.
- Teva Pharmaceutical Industries Ltd.
- Vanda Pharmaceuticals Inc.
For more information about this report visit https://www.researchandmarkets.com/research/84l79n/the_global?w=4
